PT -期刊文章盟马拉布鲁斯AU -弗农Pankratz说道盟梅雷迪思威克伦AU -沃尔特Kukull盟David Knopman AU -尼尔Graff-Radford AU -布鲁斯·米勒AU -弗朗辛拉登AU - m . Mesulam AU -布拉德利Boeve TI -额颞叶痴呆患者的受教育程度和原发性进行性失语与其他痴呆综合征(P03.089) DP - 2013年2月12日TA -神经病学PG - P03.089 P03.089 VI - 80 IP - 7补充4099 - //www.ez-admanager.com/content/80/7_Supplement/P03.089.short 4100 - //www.ez-admanager.com/content/80/7_Supplement/P03.089.full所以Neurology201首页3 2月12;80 AB -目的:确定最高教育程度高(MEA)是在行为中被变种额颞叶痴呆(bvFTD)和原发性进行性失语(PPA)相比,其他常见的痴呆症状。背景:许多老年痴呆症专家观察到病人的倾向发展bvFTD PPA,受过良好教育和成功的人在中年,早期,这种趋势似乎更频繁地发生在bvFTD / PPA比通常出现在阿尔茨海默病(AD)和路易体痴呆与下文)。生物差异,观察可能反映了如此一个世俗的影响或转诊的偏见。因为小流行病学数据存在于bvFTD / PPA,我们试图探索高意味着是否在痴呆的最大数据集对象中可以在美国国家老年协调中心(NACC)数据库。设计/方法:使用统一的数据集是在NACC数据库(数据进入9/05到12/08),意味着MEA(年)以及频率的MEA祝辞16 bvFTD之间比较,PPA,广告和下文。结果:在6457例的诊断,公元4816(74.6%),1045例(16.2%)有下文,388名(6.0%)bvFTD, 208 (3.2%) PPA。平均是14.0(年)广告,为下文13.2,14.9为PPA bvFTD和15.3。的频率是在公元16年是22.0%,15.6%,下文对PPA FTD为28.9%和32.7%。两两之间的测试组都显著(术中;0.001 Bonferroni调整后)PPA vs bvFTD除外。结论:高意味着更大的方式和频率bvFTD PPA相比,广告和下文。是否一种拮抗基因多效性和/或补偿机能亢进存在于一些个人发展bvFTD或PPA,和生物基础,需要进一步研究。支持:NIA格兰特U01 AG016976,额颞叶退化,协会和罗伯特·h·克拉丽斯史密斯和阿比盖尔范布伦阿尔茨海默病梅奥基金会的研究项目。披露:布鲁斯博士没有披露。 Dr. Pankratz received financial support for research activities from Abbott Laboratories. Dr. Wicklund has nothing to disclose. Dr. Kukull has nothing to disclose. Dr. Knopman has received personal compensation for activities with Eli Lilly & Company. Dr. Knopman has received personal compensation in an editorial capacity for Neurology. Dr. Knopman has received research support from TauRx. Dr. Graff-Radford has received personal compensation for activities with Codman. Dr. Graff-Radford has received personal compensation in an editorial capacity for the Neurologist. Dr. Graff-Radford has received research support from Janssen, Pfizer Pharmaceuticals, Medivation, Forrest, and Allon. Dr. Miller has received personal compensation for activities with Allon Therapeuctics, Inc. and TauRx Therapeutics, Ltd. Dr. Miller has received research support from Novartis. Dr Laden received financial support for research activities from IBM Corporation. Dr. Mesulam has nothing to disclose. Dr. Boeve has received research support from Cephalon, Inc.; Allon Therapeutics; and GE Healthcare.Tuesday, March 19 2013, 2:00 pm-6:30 pm